52 related articles for article (PubMed ID: 21640391)
1. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease.
Depboylu C; Schorlemmer K; Klietz M; Oertel WH; Weihe E; Höglinger GU; Schäfer MK
J Neuroimmunol; 2011 Jul; 236(1-2):39-46. PubMed ID: 21640391
[TBL] [Abstract][Full Text] [Related]
2. Validation of nigrostriatal positron emission tomography measures: critical limits.
Karimi M; Tian L; Brown CA; Flores HP; Loftin SK; Videen TO; Moerlein SM; Perlmutter JS
Ann Neurol; 2013 Mar; 73(3):390-6. PubMed ID: 23423933
[TBL] [Abstract][Full Text] [Related]
3. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration.
Chinta SJ; Kumar MJ; Hsu M; Rajagopalan S; Kaur D; Rane A; Nicholls DG; Choi J; Andersen JK
J Neurosci; 2007 Dec; 27(51):13997-4006. PubMed ID: 18094238
[TBL] [Abstract][Full Text] [Related]
4. Developmental exposure to the organochlorine insecticide endosulfan damages the nigrostriatal dopamine system in male offspring.
Wilson WW; Shapiro LP; Bradner JM; Caudle WM
Neurotoxicology; 2014 Sep; 44():279-87. PubMed ID: 25092410
[TBL] [Abstract][Full Text] [Related]
5. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.
Bartus RT; Herzog CD; Chu Y; Wilson A; Brown L; Siffert J; Johnson EM; Olanow CW; Mufson EJ; Kordower JH
Mov Disord; 2011 Jan; 26(1):27-36. PubMed ID: 21322017
[TBL] [Abstract][Full Text] [Related]
6. Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques.
Brown CA; Karimi MK; Tian L; Flores H; Su Y; Tabbal SD; Loftin SK; Moerlein SM; Perlmutter JS
Ann Neurol; 2013 Oct; 74(4):602-10. PubMed ID: 23686841
[TBL] [Abstract][Full Text] [Related]
7. Retraction Note: Gintonin Mitigates MPTP-Induced Loss of Nigrostriatal Dopaminergic Neurons and Accumulation of α-Synuclein via the Nrf2/HO-1 Pathway.
Jo MG; Ikram M; Jo MH; Yoo L; Chung KC; Nah SY; Hwang H; Rhim H; Kim MO
Mol Neurobiol; 2024 Apr; ():. PubMed ID: 38625622
[No Abstract] [Full Text] [Related]
8. Variation in complement protein C1q is not a major contributor to cognitive impairment in Parkinson's disease.
Carbutt S; Duff J; Yarnall A; Burn DJ; Hudson G
Neurosci Lett; 2015 May; 594():66-9. PubMed ID: 25817358
[TBL] [Abstract][Full Text] [Related]
9. The complement system in neurodegenerative diseases.
Nimmo J; Byrne RAJ; Daskoulidou N; Watkins LM; Carpanini SM; Zelek WM; Morgan BP
Clin Sci (Lond); 2024 Mar; 138(6):387-412. PubMed ID: 38505993
[TBL] [Abstract][Full Text] [Related]
10. New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases.
Scarian E; Viola C; Dragoni F; Di Gerlando R; Rizzo B; Diamanti L; Gagliardi S; Bordoni M; Pansarasa O
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473944
[TBL] [Abstract][Full Text] [Related]
11. Complement in Human Brain Health: Potential of Dietary Food in Relation to Neurodegenerative Diseases.
Xing Y; Zhang D; Fang L; Wang J; Liu C; Wu D; Liu X; Wang X; Min W
Foods; 2023 Sep; 12(19):. PubMed ID: 37835232
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics analysis of potential common pathogenic mechanism for carotid atherosclerosis and Parkinson's disease.
Wang Q; Xue Q
Front Aging Neurosci; 2023; 15():1202952. PubMed ID: 37649719
[TBL] [Abstract][Full Text] [Related]
13. C1q and central nervous system disorders.
Zhang W; Chen Y; Pei H
Front Immunol; 2023; 14():1145649. PubMed ID: 37033981
[TBL] [Abstract][Full Text] [Related]
14. C1q as a target molecule to treat human disease: What do mouse studies teach us?
Schulz K; Trendelenburg M
Front Immunol; 2022; 13():958273. PubMed ID: 35990646
[TBL] [Abstract][Full Text] [Related]
15. Cerebral Microstructural Alterations in Patients With Early Parkinson's Disease Detected With Quantitative Magnetic Resonance Measurements.
Klietz M; Elaman MH; Mahmoudi N; Nösel P; Ahlswede M; Wegner F; Höglinger GU; Lanfermann H; Ding XQ
Front Aging Neurosci; 2021; 13():763331. PubMed ID: 34790113
[No Abstract] [Full Text] [Related]
16. Pretreatment with Human Lactoferrin Had a Positive Effect on the Dynamics of Mouse Nigrostriatal System Recovery after Acute MPTP Exposure.
Kopaeva MY; Cherepov AB; Nesterenko MV; Zarayskaya IY
Biology (Basel); 2021 Jan; 10(1):. PubMed ID: 33401480
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.
Gavriilaki M; Kimiskidis VK; Gavriilaki E
Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114553
[TBL] [Abstract][Full Text] [Related]
18. Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease.
Jiang R; Rong C; Ke R; Meng S; Yan X; Ke H; Wu S
Medicine (Baltimore); 2019 Oct; 98(41):e17478. PubMed ID: 31593110
[TBL] [Abstract][Full Text] [Related]
19. Immune Signaling in Neurodegeneration.
Hammond TR; Marsh SE; Stevens B
Immunity; 2019 Apr; 50(4):955-974. PubMed ID: 30995509
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System.
Carpanini SM; Torvell M; Morgan BP
Front Immunol; 2019; 10():362. PubMed ID: 30886620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
